LIVING TO 120? THE MIDDLE EAST LEADS AI’S HEALTHCARE REVOLUTION

By Federico Pienovi, CEO for APAC & MENA at Globant

When technologies go exponential, even experts are caught off guard. Generative AI is one of those inflection points and nowhere is this tension more profound than in healthcare and aging, particularly in the Gulf region where demographic realities are driving unprecedented transformation. In Saudi Arabia, the population over 60 is expected to increase fivefold by mid-century, making longevity no longer just a Western debate but a Middle Eastern economic and social reality where AI moves from optional to existential.

While most organizations struggle to operationalize AI beyond demos, Saudi Arabia and the UAE are building system-level infrastructure that represents the real story. Saudi Arabia is embedding AI throughout its healthcare system through Vision 2030, with the Saudi Genome Program using multi-omics data—genomics, proteomics, metabolomics—and AI to shift from reactive to predictive care, moving beyond isolated diagnostics toward continuous early detection models.

Riyadh recently showcased the world’s first fully robotic heart transplant, CAR-T cell therapy advancements, VR-based medical education, and mobile stroke units with advanced diagnostics, while digital twin technology and precision medicine are becoming standard rather than experimental. These initiatives reflect a national longevity strategy that positions geroscience research and personalized digital twins as core infrastructure, with private-sector innovators like Rewind building AI-powered diagnostics to prevent disease before it emerges.

The UAE has gone even further, treating longevity as a national industry with Abu Dhabi’s Pura Longevity Clinic offering AI-integrated assessments and personalized prevention programs that combine nutrition, sleep, fitness, and mental health services, positioning longevity medicine as mainstream rather than elite. Dubai aims to become the global capital of “well-care”, biohacking, stem-cell therapies, and AI-driven anti-aging, as part of a broader strategy to engineer the “100-year life” through advanced preventive and regenerative medicine.

The UAE now hosts 680 longevity companies and 670 investors across 100 innovation hubs spanning PharmTech, telemedicine, advanced cosmetics, mental health, and wellness, making longevity a full economic sector. The Institute for Healthier Living Abu Dhabi is building a Healthy Longevity Medicine ecosystem with longevity-focused clinical care, innovation hubs, and population health research, while government-level commitment is evident through Abu Dhabi’s Department of Health convening global forums to accelerate personalized healthcare and longevity science.

Beyond the Hype: The Human Element

But here’s the uncomfortable truth: more AI doesn’t automatically mean better health. Like millions of others tracking sleep, monitoring recovery, and measuring stress variability, we risk becoming surrounded by dashboards of health metrics where everything is quantified and notified, yet the more data we collect, the more a critical question emerges—are we actually healthier, or simply more informed about our anxiety?

The healthcare system risks repeating the same mistake enterprises made with digital transformation, adding layers of technology without redesigning the underlying architecture, creating more apps, more portals, more fragmented experiences, with noise disguised as progress.

Harvard Medical School researchers have highlighted how AI can already match or exceed clinicians in specific diagnostic tasks, particularly in imaging and pattern recognition, while MIT’s Jameel Clinic has demonstrated how machine learning models can accelerate drug discovery cycles from years to months, and McKinsey estimates that generative AI could unlock up to $100 billion annually in value across pharma and medical products alone.

Yet the promise of AI in aging is not about adding intelligence everywhere,it’s about reducing friction and elevating judgment through agentic AI systems capable of orchestrating actions autonomously across complex environments, moving healthcare from reactive to anticipatory with adaptive health pathways tailored to biology, behavior, and environment instead of generic wellness advice.

We must be careful because biology is not software, data can be biased, predictions can be misinterpreted, and AI systems trained predominantly on specific datasets may fail in other populations, making governance, explainability, and medical accountability foundational requirements rather than afterthoughts.

The Bigger Picture

From a technology executive’s perspective, the next decade will redefine healthcare economics as systems shift from hospital-centered to prevention-centered models, payment structures evolve toward outcome-based frameworks, and AI doesn’t replace physicians but enables those who leverage it to outperform those who don’t.

The Middle East understands this transformation, with the UAE’s push into genomics and Saudi Arabia’s investments in biotech and digital health reflecting recognition that longevity will shape national competitiveness, where healthy lifespan, not just GDP, will define prosperity.

In these nations where governments are investing heavily in smart hospitals, genomics programs, and national AI strategies, the opportunity is enormous as they position themselves as global hubs for the future of healthspan and aging, demonstrating that AI is moving from experimentation to infrastructure with longevity becoming a national economic and healthcare priority.